Hematologist
CION Cancer Clinics
Fixed-duration or continuous treatment for CLL: how to choose | CION Cancer Clinics
Fixed-duration CLL treatment, usually venetoclax-based, runs for a set period of about one to two years and then stops. Continuous treatment is a daily BTK inhibitor tablet taken for as long as it keeps the CLL controlled. Neither is better for everyone. This page compares them, explains who each does not suit, and lists what to ask before deciding. At CION Cancer Clinics, every leukaemia, MDS and MPN case is reviewed by our haematologist and discussed at a tumour board before a plan is agreed.
BP
Medically reviewed by Dr. Basudev PokhrelConsultant Haematologist · last reviewed September 2026, next review due September 2027
17+specialists on panel
15,000+patients treated
35+centres across Telangana & AP
4.8★ / 800+Google rating
On this page
- What is the difference between fixed-duration and continuous CLL treatment?
- How do the two approaches compare day to day?
- Which treatments fall into each group?
- Who is each approach not right for?
- How is the choice made for your CLL?
- What do families often misunderstand about this choice?
- What should you ask before deciding?
- Common questions about fixed and continuous CLL treatment
The short answer
What is the difference between fixed-duration and continuous CLL treatment?
Fixed-duration treatment runs for a set period, often about one to two years, and then stops even if you are well. Continuous treatment is a daily tablet taken for as long as it keeps the CLL under control and the side effects stay manageable, which can mean many years.
Why both exist
Modern CLL medicines can work in two different ways. Venetoclax-based combinations can clear CLL cells so deeply that treatment can stop and the disease often stays quiet for a long time afterwards. BTK inhibitors, such as ibrutinib, acalabrutinib and zanubrutinib, hold the CLL down steadily but rarely clear it, so they are kept going.
Neither is simply stronger
Studies have not shown one approach to be better for everyone. The right choice depends on the genetic tests on your CLL cells, your heart and kidney health, the other medicines you take, how easily you can reach a laboratory, and what matters most to you. Some people value a clear end date. Others prefer a tablet with a simple start and no ramp-up.
What happens when fixed-duration treatment ends
You go back to regular check-ups, much like watch and wait. If the CLL returns later, treatment can often be restarted, sometimes with the same medicine again. Your haematologist will explain what the plan would be.
What this page cannot tell you
It cannot tell you which approach is right for your CLL, how long a response will last, or what your outlook is. Those answers depend on your own test results, your general health and how your disease has behaved so far. Use this page to prepare questions, and bring the reports, the medicine list and a family member to the consultation where the choice is made.
Side by side
How do the two approaches compare day to day?
Fixed-duration
Continuous
Has a planned stop date agreed at the start
No set end; carries on while it is working
Venetoclax needs a careful weekly ramp-up with frequent blood tests
BTK tablets start at the full dose, with fewer early tests
Often includes antibody drips in the first months
Usually tablets alone, taken at home
Side effects end when treatment ends
Side effects must be lived with for years
Medicine cost is limited to the treatment period
Medicine cost continues month after month
The options
Which treatments fall into each group?
Names change as new studies report. These are the combinations families most often hear about.
Venetoclax with obinutuzumab
A tablet plus an antibody drip, given for about a year in total. It is a common first treatment for people who want a stop date.
Venetoclax with ibrutinib
Two tablets combined for a fixed period. It avoids drips, but it joins the side effects of both medicines, so it needs careful selection.
BTK inhibitors on their own
Ibrutinib, acalabrutinib or zanubrutinib, taken every day without a planned end.
Often favoured when
- TP53 or del(17p) changes are present
- Frequent blood tests are hard to reach
- Kidney function is poor
Chemo-immunotherapy
Older fixed-duration combinations such as FCR are used far less now. They may still suit a small group of younger, fit people with certain test results, or where newer medicines cannot be accessed.
Not sure whether this applies to you?
Ask an oncologistBeing honest about fit
Who is each approach not right for?
Every option leaves someone out. Knowing where you fall saves time in the consultation and avoids a plan that looks good on paper but does not fit your life.
When fixed-duration may not suit you
If your CLL carries a TP53 change or del(17p), the disease tends to come back sooner after a fixed course, and many haematologists prefer continuous treatment. The venetoclax ramp-up also asks a lot: extra water, repeated blood tests and sometimes a hospital stay. People with weak kidneys, or who live far from a laboratory, may find this hard.
When continuous treatment may not suit you
BTK inhibitors can raise blood pressure, cause an irregular heartbeat and increase bleeding. People with existing heart rhythm problems, poorly controlled blood pressure or who take blood thinners need careful thought. Some people also find that years of daily tablets and side effects wear them down.
When the cost pattern matters
A continuous plan means paying for medicine every month for as long as it lasts. A fixed plan concentrates the cost into a shorter period. Talk openly about this, because a plan that cannot be kept up is not a safe plan.
Reaching a decision
How is the choice made for your CLL?
Genetic tests on the CLL cells
IGHV status and TP53 or del(17p) results show how the disease is likely to behave. They are usually done before first treatment and repeated before later treatment.
A look at your wider health
Your heart, blood pressure, kidneys, other illnesses and every medicine you take are reviewed, because each option has its own side effects to fit around.
Case discussion
At CION, your case is discussed at a tumour board so the plan reflects more than one specialist's view.
Your priorities
Travel, work, family support, cost and how you feel about a stop date are all fair to raise. The choice is made with you, not for you.
Commonly believed
What do families often misunderstand about this choice?
"Stopping treatment means the doctors have given up."
In a fixed-duration plan, stopping is the plan. It is agreed on the first day, and it happens because the treatment has done its job, not because hope has run out.
"Continuous treatment means the CLL is worse."
Not necessarily. Many people choose a BTK tablet because it fits their health or daily life better. It says little about how serious their disease is.
"Once the CLL is controlled, we can quietly stop the daily tablet."
Stopping a continuous medicine without your haematologist can let the CLL flare. Any change to treatment should be planned with the team.
"If the CLL comes back after a fixed course, nothing more can be done."
Several treatment options usually remain. Some people receive the same medicine again, and others move to a different group. Your haematologist will look at how long the first response lasted.
Take this with you
What should you ask before deciding?
- What do my IGHV and TP53 results mean for this choice?
- How long would the fixed plan last, and what happens after?
- Which side effects would matter most with my heart or kidneys?
- How many blood tests and hospital visits does each option need?
- What would the monthly and total medicine cost look like?
- What would we do if the CLL comes back?
Questions we are asked
Common questions about fixed and continuous CLL treatment
Which is better, fixed-duration or continuous treatment?
Neither is better for everyone. Both approaches control CLL well in studies. The right one for you depends on your genetic test results, heart and kidney health, other medicines, access to blood tests and what you want from treatment. Your haematologist should explain why one is suggested.
How long does fixed-duration treatment last?
It depends on the combination. Venetoclax with obinutuzumab runs for about a year. Some other combinations run a little longer. Your plan will state the expected end date at the start, though it can shift if treatment is paused for side effects.
If I am on continuous treatment, will I take it for life?
Possibly for many years. It continues while it keeps the CLL controlled and the side effects are acceptable. It may be changed if the disease stops responding or side effects become too much. That decision is made by your haematologist, not on your own.
What is MRD, and does it decide when treatment stops?
MRD means measurable residual disease: tiny numbers of CLL cells found by very sensitive tests. Undetectable MRD at the end of a fixed course is a good sign. In routine care, the stop date is usually fixed in advance rather than guided by MRD alone.
Can I switch from one approach to the other?
Yes, switches happen, usually because of side effects or because the CLL has stopped responding. Switching is a planned decision with your haematology team. Never stop one medicine and start another on your own.
Do the tablets interact with my heart or blood pressure medicines?
Some do. BTK inhibitors can interact with blood thinners, and venetoclax levels are raised by certain antifungal and heart medicines. Bring every medicine, including Ayurvedic and herbal products, to your appointment so the team can check them.
Does my age decide which plan I get?
Age alone does not decide it. Fitness, other illnesses and kidney function matter more. Many older people take either approach safely. The older chemo-immunotherapy combinations are the ones where age and fitness weigh most heavily.
Are these medicines covered by schemes or insurance?
It varies by scheme, policy and medicine, and the rules change. Check the current terms of Aarogyasri, CGHS, ECHS, EHS, PM-JAY or your insurer. The CION helpline can help you understand what your own cover includes before a plan is chosen.
Your Haematologist
Meet CION's haematologist. One specialist for your blood report and your plan.
Dr. Basudev Pokhrel reviews blood counts, transfusion needs and blood disorders, and works with the CION tumour board on blood cancers.
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Sources
- National Cancer Institute — Chronic Lymphocytic Leukemia Treatment (PDQ) - Patient Version
- Cancer Research UK — Treatment for chronic lymphocytic leukaemia (CLL)
- Leukaemia & Lymphoma Society — Chronic lymphocytic leukemia
- Blood Cancer UK — Chronic lymphocytic leukaemia (CLL)
This page is general information, not a prescription. Do not change or stop any treatment based on what you read here. If anything is worrying you, contact your own treating team — or call our helpline and we will help you reach the right specialist.
Keep reading
Related pages
Talk to us
Weighing up CLL treatment options?
Share your reports and test results with us. CION's haematology team will talk through which approach fits your situation. One helpline serves every CION centre.